Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Un-(User Fee) Funded Priorities

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency tells stakeholders that five PDUFA proposals which were not included in the commitment letter will be funded with existing resources.
Advertisement

Related Content

FDA Ponders Trimming PDUFA Programs
FDA Ponders Trimming PDUFA Programs
Does PDUFA Need A Haircut? FDA Ponders Trimming Its Responsibilities
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
FDA Appropriations Debate Moves To Senate, And From "Hard Science" To Harder Numbers
FDA Appropriations Debate Moves To Senate, And From "Hard Science" To Harder Numbers
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers
PDUFA V Agreement Appears Set Between FDA And Industry

Topics

Advertisement
UsernamePublicRestriction

Register

PS072510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel